Wire · opportunities
QurAlis Receives FDA Clearance for IND Application of QRL-201 for the Treatment of ALS ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 November 2026 · Fusion42 review
QurAlis has received FDA clearance for the IND application of QRL-201, a first-in-class antisense oligonucleotide therapeutic targeting ALS, enabling it to initiate a pivotal clinical trial in the U.S. The ANQUR clinical trial's final data demonstrated that QRL-201 significantly slowed ALS progression by 50% and reduced key biomarkers of axonal damage, showing promise for modifying disease outcomes.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 16 Nov 2026 and 20 Nov 2026.
◆ ◆ The Wire takeaway
You now have a clear regulatory path to run a pivotal ALS trial in the U.S. Moving fast to prepare for the 2027 CONQUR trial start date will put you ahead in precision ALS therapeutics.
◆ Coverage
3 sources · first reported 16 Nov 2026 · latest 20 Nov 2026
◆ Related on Wire
◆ Topics